Skip to main content
 
Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

See our updated masking policy »

Stanford Health Care

USE OF OKT3 WITH CICLOSPORIN AND STEROIDS FOR REVERSAL OF ACUTE KIDNEY AND LIVER ALLOGRAFT-REJECTION NEPHRON Fung, J. J., Demetris, A. J., Porter, K. A., Iwatsuki, S., Gordon, R. D., Esquivel, C. O., Jaffe, R., Tzakis, A., Shaw, B. W., Starzl, T. E. 1987; 46: 19-33

Abstract

OKT3 monoclonal antibody therapy was added to preexisting baseline immunosuppressive treatment with ciclosporin and steroids to treat rejection in 52 recipients of cadaveric livers and 10 recipients of cadaveric kidneys. Rejection was controlled in 75% of patients treated, often after high-dose steroid therapy had failed. Rejection recurred during the 17-month follow-up period, after completion of OKT3, in only 25% of the patients who had responded. The safety and effectiveness of this monoclonal therapy, added to ciclosporin and steroids, has been established in this study.

View details for Web of Science ID A1987J437000004

View details for PubMedID 3306422

View details for PubMedCentralID PMC2994552